Register for our free email digests:
The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.
Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.
Despite the further genericization of statins and ezetimibe, the arrival of expensive new therapies means the dyslipidemia market is still set for growth over the next eight years, say analysts from Datamonitor Healthcare.
Enter your clinical research team, novel trial design, outstanding results and more for Informa Pharma Intelligence’s 2018 Clinical and Research Excellence (CARE) Awards.
Recent Tweets from Scrip
Tweets from https://twitter.com/IBI_Tweets/lists/scrip-tweets
Commercial Explore this Topic
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – first up are responses from small biotechs.
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.
The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.
AstraZeneca and Merck & Co's strategic collaboration on the development of olaparib and other anticancers has the US breast cancer sector in its sights, with approval of a US sNDA in the indication expected in early 2018.
Panacea Biotec has received another piece of good news as it strives to return to profit – this time from Ukraine which has awarded a GMP certificate to the Indian drug firm to supply 22 medicinal products to the country. It also opens up 49 other nations for the firm’s products.
Emerging Company Profile: HemoShear thinks its REVEAL-tx platform can identify novel targets and validate drug candidates better than existing bench research methods. Japan’s Takeda is betting in a new collaboration that HemoShear can deliver novel targets in NASH.
Pfizer appoints new leadership in Japan amid sluggish growth. Top executive changes also made at Novo Nordisk and Stryker in China, Hutchison MediTech and Boston Scientific in the Asia Pacific.
Policy & Regulation Explore this Topic
Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer.
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
No European approval recommendation for Roche multiple sclerosis drug Ocrevus but the Swiss major tells Scrip it is hopeful of getting approval within four months.
Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.
Research & Development Explore this Topic
China-based but UK- and US-quoted Chi-Med is building up clinical data for its late-stage anticancer savolitinib, this time in patients with treatment-refractory lung cancer.
China FDA has granted earlier-than-expected approval to begin a Phase III clinical trial of ViroMed's gene therapy VM202. Successful trials in China are expected to support global commercialization of the first-in-class therapy for cardiovascular and neurological diseases, which is also in late-stage clinical development in the US.
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.